Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat

Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential

August 4, 2020 9:10 AM EDT

Piper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining an Overweight rating, citing Ingrezza sales and volumes, a cinrecerfront Phase III study in CAH patients, an increasingly deep pipeline, and the low rates of TD... More